Pharmacodynamic Analysis of Daptomycin-treated Enterococcal Bacteremia: It Is Time to Change the Breakpoint.
Published in Clinical infectious diseases : an official publication of the Infectious Diseases Society of America • May 2, 2019
Authors:,,
Lindsay M Avery
Joseph L Kuti
Maja Weisser
Abstract
BACKGROUND: Currently, there is debate over whether the daptomycin susceptibility breakpoint for enterococci (ie, minimum inhibitory concentration [MIC] ≤4 mg/L) is appropriate. In bacteremia, observational data support prescription of high doses (>8 mg/kg). However, pharmacodynamic targets associat...
Finding related papers...
Discussions
(0)No comments yet
Be the first to share your thoughts!